

Chikungunya Outbreak in Bangladesh (2017): Clinical and hematological findings

Saeed Anwar^{1,†}, Jarin Taslem Mourosi^{1,†}, Md. Fahim Khan^{1,†}, Mohammad Ohid Ullah², Olivier M. Vanakker³, Mohammad Jakir Hosen^{1,*}

¹Department of Genetic Engineering and Biotechnology, School of Life Sciences, Shahjalal University of Science and Technology, Sylhet 3114, Bangladesh

²Department of Statistics, School of Physical Sciences, Shahjalal University of Science and Technology, Sylhet 3114, Bangladesh

³Center for Medical Genetics, Ghent University Hospital, 9000 Ghent, Belgium

[†]These authors have contributed equally to this work.

***Correspondence:** Prof. Dr. Mohammad Jakir Hosen, Department of Genetic Engineering and Biotechnology, School of Life Sciences, Shahjalal University of Science and Technology, Sylhet 3114, Bangladesh. Email: jakir-gen@sust.edu. Cell Phone: +88 01777 195 857. ORCID: 0000-0001-6444-0214.

Running title: Clinical and hematological findings of Chikungunya

Keywords: Chikungunya, clinical features, hematological features, long term effect, Bangladesh.

Abstract

A massive outbreak of Chikungunya occurred in Bangladesh during the period of April-September, 2017 and over two million people were at risk of getting infected by the virus. A prospective cohort of viremic patients was constituted and analyzed to define the clinical, hematological and long-term aspects of this outbreak. A 35-day long comprehensive survey was conducted in two major, neighboring cities, Dhaka and Mymensingh. One-hundred and eighty-seven clinically proven Chikungunya cases were enrolled in the cross-sectional cohort study. Additionally, a smaller group of 48 Chikungunya patients was monitored for post-infection effects for 12 months. Clinical data revealed that a combination of fever and arthralgia (oligoarthralgia and/or polyarthralgia) was the cardinal hallmark (97.9% of cases) of the infection. Hematological analysis showed that, irrespective of age groups, hemoglobin level significantly decreased and erythrocyte sedimentation rate remarkably increased in Chikungunya confirmed patients. However, the majority of the patients had a normal range of whole WBC and platelet counts; RBC counts for mid aged (40 – 60 years) and senior (61+ years) patients (especially in the females) were beyond the reference values. The post-infection study revealed that children had an early recovery from the infection compared to the adults. Moreover, post-infection weakness, successive relapse of arthralgic pain and memory problems were the most significant aftereffects, which had an impact on daily activities of patients. This study represents a comprehensive overview of clinical and epidemiological features of the 2017 outbreak of Chikungunya in Bangladesh as well as its chronic outcomes till the 12th month. It provides insights into the natural history of this disease which may help to improve management of the Chikungunya patients.

Author summery

The clinical profile, epidemiology and the economic impacts during the acute phase of Chikungunya infection has been studied quite rigorously. However, studies regarding the hematological features and chronic consequences are very limited. In this study, a dataset of 187 clinically proven chikungunya patients were analyzed for the clinical and hematological features at acute phase of the infection. Additionally, the long-term consequences till month 12 after the infection were studied for a smaller group of 48 patients. Clinical data revealed that a combination of fever and joint pain (arthralgia) was the cardinal hallmark in the acute phase of the infection. Hematological analysis showed that, hemoglobin levels of the patients were significantly reduced and erythrocyte sedimentation rate increased remarkably. Also, RBC counts for mid-aged and older patients were beyond the reference values. The post-infection consequence study unveiled that children recovered better from the infection compared to the adults. Further, post-infection weakness, successive relapse of joint pain and memory problems were the most significant aftereffects. Overall, the infection had moderate to severe impact on daily activities of the respondents. This study provides insights into the clinical and hematological aspects of Chikungunya infection during the acute phase as well as describes an account for its chronic outcomes which puts forward to the knowledge for clinicians and epidemiologists regarding the infection diversity and to help improved patient management.

1 Introduction

2 Chikungunya is a neglected tropical disease, usually endemic to Africa, Southern and
3 Southeast Asia. This disease is caused by the Chikungunya virus (ChikV), a classical arbovirus
4 which possesses a single stranded positive-sense RNA genome that is transmitted to human
5 through the bites of infected female *Aedes* mosquitoes, predominantly by *Aedes aegypti* and
6 *Aedes albopictus* [1-4]. In classical Chikungunya, after a short incubation period of about 1 to
7 5 days, acute commencement of fever and polyarthralgia, most eminently affecting the limb
8 extremities, are the most frequently reported clinical signs in 72-97% of cases [1, 3, 5]. Other
9 symptoms include skin rash, headaches, back pain, myalgia and nausea [2, 6, 7]. Joint pain can
10 often be severe and may remain indefatigable for weeks to years. The most severe forms of the
11 disease which have been reported are associated with neurological, cardiovascular, hepatic,
12 dermatological or respiratory symptoms along with miscarriages and neonatal infections [8-
13 14]. Despite the fact that only few patients require hospitalization, there have been a few reports
14 of fatalities due to this infection [15-18]. The clinical manifestations of Chikungunya are often
15 confused with Dengue, especially in regions where both diseases can have outbreaks.

16 Till now, outbreaks of Chikungunya have been reported in more than 60 countries [7].
17 The first Chikungunya outbreak in Bangladesh was recognized in 2008 in two villages of
18 northwestern Bangladesh [19]. Later, in November 2011, another Chikungunya outbreak was
19 reported in Dhaka [20]. The most dangerous outbreak of Chikungunya in Bangladesh was
20 reported in April – September 2017, when a huge number of positive cases were reported from
21 23 districts of the country; 13000 clinically confirmed cases were documented in the city of
22 Dhaka alone [21-27]. The ChikV from the 2017 outbreak in Dhaka was found to be genetically
23 distinct from the strain found in the previous outbreak, Bangladesh/0810atw [28]. Phylogenetic
24 analysis revealed that the outbreak strains constituted a new cluster within the Indian Ocean

clade, suggesting that they are novel variants [29]. Together with variability in symptoms, 83% of patients in Dhaka also had low to very low overall quality of life, and ~30% patients had ambulatory problems due to severe arthropathy [30]. However, the impact of ChikV on hematological parameters and its long-term effects have not yet been studied. In this study, hematological parameters were assessed during the Chikungunya 2017 outbreaks in a cohort of 187 patients; a subgroup of these was continuously followed afterwards to better understand the long-term effects.

Materials and Methods

Patient recruitment, sample collection and data analysis

During the period of June 30, 2017 to August 4, 2017, 187 clinically confirmed, RT-PCR or serological test positive patients from Dhaka and Mymensingh were recruited randomly in this study (**Fig 1**). A cross-sectional study was done to investigate the clinical, biochemical and hematological profiling, and a long-term follow-up was conducted to understand the after effect of Chikungunya on the quality of life. Only clinically proven Chikungunya patients were included; patients with respiratory and cardiovascular symptoms, previous report of arthralgia, any kind of arthritis, rheumatism, any major recent injuries or blood disorders were excluded from the study. Patients with proven evidence of previous or present infection by Dengue virus were also not included in the study. Among the 187 enrolled patients, 48 were found willing to follow a long-term monitoring scheme of 12 months (Long term consequence assessment group; LCA) (**Fig 1**).

Fig 1: A schematic illustration of key features and work flow for the study.

Ethics Statement

The methodology and protocol used for this study was reviewed and endorsed by the Graduate Research Ethics Committee, (Headed by the Dean) School of Life Sciences, Shahjalal University of Science and Technology. All participants or their legal representative gave written informed consent according to the Declaration of Helsinki.

Sero-biochemical and long-term effect study

Biochemical and serological test results were collected after they were prescribed and performed by a specialist physician and a specialist diagnostic center respectively. Relative intensity of joint pain was evaluated using a numerical rating (NR) scale starting from 0 to 10. A rating of 0 indicated that the individual had no joint pain, and a rating of 10 indicates intolerable joint pain. Using these relative scores given by the patients, the pain intensity was categorized as mild (NR 1 – 4), moderate (NR 5 – 7) and severe (8 – 10). The anatomical location(s) of the pain and how long it existed after ChikV infection were also documented. For long-term consequences assessment (LCA) of the after-effect of Chikungunya, consented patients were interviewed with a standard questionnaire 2, 4, 6, 9 and 12 months after the viremic phase (M2, M4, M6, M9 and M12) (**S2 Questionnaire**). Data were analyzed using SPSS (Statistical Package for Social Sciences) and statistical significance was tested using both one-tailed and two-tailed experiments including Student T-test, z statistic, χ^2 test and McNemar tests (for matched pairs of subjects) at a 99% ($p = 0.01$) and 95% ($p = 0.05$) confidence level.

Results

Features of the patient's cohort

Among the 187 confirmed (using RT-PCR and/or immunological techniques) Chikungunya (**Table 1**) patients, 117 (62.6%) patients were from the Dhaka region, while 70

(37.4%) were from Mymensingh. Interestingly, 18 patients from Mymensingh reported that they travelled to Dhaka in the weeks before the inclusion. The age range of ChikV positive patients was between 3 and 84 years, with the majority of cases involving the age group 41-59 years (**Fig 2**). Also, 32 children (≤ 15 yrs) were included in this study.

Fig 2: Age and gender distribution of the sample pool.

Table 1: Diagnostic outcomes of sero-samples

Parameter	Finally enrolled patients n (%)	LCA group n (%)
Total number of patients	187 (100%)	47 (100)
By Immunochromatography	135 (72.2%)	
By IgM ELISA	48 (25.7%)	
By both immunochromatography and IgM ELISA	4 (2.1%)	

LCA: Long-term consequence assessment; n: number of respondents

Demographic Data

Randomly collected samples and demographic data analysis revealed that females were more prone to Chikungunya (M:F=1:1.34) (**Table 2**). Among 187 patients, 2 were admitted to a hospital and most of the patients visited doctors and/or a diagnostic center within, on average, 5.1 days after the first symptoms.

Table 2: Demographic features of ChikV positive patients

Characteristics	Finally enrolled patients Value	LCA group Value
Male: Female (Ratio)	1:1.34	1:1.04
Mean years of age \pm Standard Deviation (Female)	38.5 \pm 15.56	33.42 \pm 8.52

Mean years of age \pm Standard Deviation (Male)	29 \pm 17.58	33.44 \pm 11.42
Time from onset to diagnostic center visit (Mean days \pm Standard Deviation)	5.1 \pm 2.9	4.8 \pm 2.6
Hospitalization	2 (0.54%)	0 (0.0%)

LCA: Long-term consequence assessment

82 Signs, Symptoms and Clinical Features

83 The symptoms of ChikV infected patients are presented in **Table 3**. The most common
84 feature of the ChikV infection was high fever (39.88°C on average) and arthralgia, found to be
85 present in ~98% of patients. Arthralgic pain was more frequently reported between day 1 to 3
86 in the infected persons, while fever was more prominent at day 4 or 5, myalgia between days
87 4 to 6, skin rashes between 6 to 7 days and itching on day 7. Other noticeable symptoms
88 included swelling, stiffness and redness of joints, itching, headache, cough, insomnia, fatigue
89 and dizziness.

90 *Table 3: Signs and symptoms recorded from ChikV positive patients during acute phase*

Symptoms	Presence (%)	Presence for (days; median)
Fever	97.9 ^a	5.5
Arthralgia	97.9	17.5
Oligoarthralgia	43.75	
Polyarthralgia	56.25	
Continuous pain	72.72	18.5
Myalgia	68.8	8
Swelling of joints	72.9	
Stiffness of joints	52.1	
Redness of joints	27.1	3

Clinical and hematological manifestation of Chikungunya

Symmetrical trend of pain	62.5	
Pain-fever correlation	52.1	
Headache	62.5 ^b	
Enophthalmos/eye irritation/pain	3.7	4
Redness of eye	64.17	3
Throat pain	18.75	4
Sore in mouth/oral ulcer	29.2	5
Dizziness	58.3	
Dysentery-like symptom	52.1 ^c	
Fatigue	54.2	
Disturbance of sleep	64.6	7.5
Rash	79.2	3
Itching	70.8	3
Catarrh-cough	43.75	
Gastrointestinal	18.1	
Respiratory	10.7	
Hospitalization	2.1	4.5

^a~2/3rd reported continuous fever

^b1/3rd reported severe and continuous headache

^chalf of the patients had dysentery during the whole course of disease

Arthralgia was observed at 12 different anatomical sites (**Fig 3**), with hand joints (fingers and wrist), leg joints (ankle, knee and feet), and shoulder and neck joints being most often affected in the Chikungunya patients. Importantly, arthralgia was typically symmetrical. The intensity of the pain was stronger when patients tried to move. None of the patients reported arthralgia specific to a single anatomical site. Other signs and symptoms which were less frequent included gastrointestinal (GI) and respiratory (RD) complaints.

Fig 3: Sites of pain due to Chikungunya infection

The signs and symptoms pattern of Chikungunya seemed remarkably different in children compared to adults (**Table 4**). Arthralgia was less present while vomiting was more frequently reported in children. In addition, the frequency of skin rash was notably higher.

Table 4: Differences in clinical manifestations of ChikV positive children and adults

	Children (≤ 15 yrs) (%)	Adults (> 15 yrs) (%)	<i>p</i> value*
Symptoms at onset (day 0 – day 7)			
Arthralgia	87.5	100	< 0.0001
Headache	84.4	57.4	< 0.0001
Rash	37.5	87.7	< 0.0001
Itching	43.75	76.1	< 0.0001
Vomiting	64.25	25	< 0.0001
Symptoms at day 60			
Arthralgia	15.6	37.5	< 0.0001
Headache	00.0	8.33	< 0.0001
Vomiting/vomiting tendency	00.0	10.4**	< 0.0001

*Calculated from *t*-test

**All respondents were females

Hematological Findings

Hematological analysis of ChikV positive patients revealed that hemoglobin level was significantly low in both children and adults compared to standard reference value (**Table 5**). For ChikV positive patients, the complete white blood cell (WBC) counts ranged from 2 to 12.6 K/ μ L, of which neutrophil (NTP) counts ranged between 32-80% and lymphocyte (LPC) counts ranged between 14 – 56%. Platelet counts ranged from 85 K/ μ L to 547 K/ μ L. Although

the majority of the ChikV positive patients were within normal ranges for whole WBC, neutrophils, LPC and platelets (PLT), many patients represented varying degrees of lymphopenia when compared to reference values (Fig 4).

Table 5: Hematological findings in ChikV positive patients according to age groups

Age group (yrs)	Median	Range	Within reference value n (%)	Beyond reference value n (%)	p value*
Hemoglobin level in g/dL (Reference range for male: 12 – 17 g/dL, female: 11.5 – 15.5 g/dL)					
Children (1 - 15)	11.55	7.82 - 15.2	12 (37.5)	20 (62.5)	0.015822
Young (16 - 25)	13	9.5 - 15.6	19 (79.17)	5 (20.83)	0.001546
Mid Aged (26 - 40)	12.4	8.9 - 15.6	37 (63.79)	21 (36.21)	0.002727
Seniors (41 - 59)	12.1	8.1 - 14.9	27 (44.26)	34 (55.74)	0.012039
Old (60+)	10.55	9 - 13.2	5 (41.67)	7 (58.33)	6.20e-05
Total			100 (53.48)	87 (46.52)	
ESR in mm in 1st hour (Reference range for male: 0 - 10 mm in 1st hour, female: 0 - 20 mm in 1st hour)					
Children (1 – 15)	M: 23, F: 25	4 - 164	8, 25)	24 (75)	< 0.00001
Young (16 - 25)	M: 30, F: 23	3 - 60	12 (50)	12 (50)	< 0.00001
Mid Aged (26 - 40)	M: 12, F: 24	3 - 111	20 (34.48)	38 (65.52)	< 0.00001
Seniors (41 - 59)	M: 13.5, F: 28	5 - 103	13 (21.31)	48 (78.69)	< 0.00001
Old (60+)	M: 16.5, F: 31	12 - 101	1 (8.33)	11 (91.67)	-
Total			54 (28.88)	133 (71.12)	
RBC count in M/μL (Reference range: 4.2 – 6.2 M/μL)					
Children (1 - 15)	4.4	3.7 - 5.66	27 (84.38)	5 (15.62)	6.9e-05
Young (16 - 25)	4.8	3.9 - 5.65	21 (87.50)	3 (12.50)	< 0.00001
Mid Aged (26 - 40)	4.6	3.8 - 6.4	11 (18.97)	47 (81.03)	0.415072
Seniors (41 - 59)	4.4	3.2 - 6.22	17 (27.87)	44 (72.13)	0.251382

Clinical and hematological manifestation of Chikungunya

Old (60 ⁺)	4.2	3.4 - 4.38	8 (75)	4 (25)	0.296948
Total			84 (44.92)	103 (55.08)	

WBC count in K/ μ L (Reference range: 4.8 – 10.8 K/ μ L)

Children (1 - 15)	6.725	4 - 12.2	17 (53.12)	15 (46.88)	0.895775
Young (16 - 25)	6	4.4 - 10.5	18 (75)	6 (25)	< 0.00001
Mid Aged (26 - 40)	6	3.7 - 12.5	39 (67.24)	19 (32.75)	0.929082
Seniors (41 - 59)	5.9	2 - 12.6	40 (65.57)	21 (34.43)	0.530659
Old (60 ⁺)	8	3 - 10.6	8 (75)	4 (25)	< 0.00001
Total			122 (65.24)	65 (34.76)	

Neutrophil part in % (Reference range: 40 – 70 %)

Children (1 - 15)	57.5	37 - 72	29 (90.63)	3 (9.37)	0.675216
Young (16 - 25)	61.5	32 - 80	14 (58.33)	10 (41.67)	0.269463
Mid Aged (26 - 40)	64	40 - 80	47 (81.03)	11 (18.97)	0.005389
Seniors (41 - 59)	62	52 - 75	58 (95.08)	3 (4.92)	< 0.00001
Old (60 ⁺)	66.5	46 - 75	10 (83.33)	2 (16.67)	< 0.00001
Total			158 (84.50)	29 (15.50)	

Lymphocyte part in % (Reference range: 20 – 45 %)

Children (1 - 15)	35	23 - 55	29 (90.63)	3 (9.37)	< 0.00001
Young (16 - 25)	27.5	15 - 52	18 (75)	6 (25)	0.985798
Mid Aged (26 - 40)	30	14 - 56	46 (79.31)	12 (20.69)	0.871306
Seniors (41 - 59)	33	17 - 42	60 (98.36)	1 (1.64)	-
Old (60 ⁺)	28	17 - 42	11 (91.67)	1 (8.33)	-
Total			164 (87.70)	23 (12.29)	

Platelets count in K/ μ L (Reference range: 150 – 500 K/ μ L)

Children (1 - 15)	263.5	115 - 505	29 (90.63)	3 (9.37)	0.883132
Young (16 - 25)	226.5	135 - 515	21 (87.5)	3 (12.5)	0.871306
Mid Aged (26 - 40)	229	150 - 547	56 (96.55)	2 (3.45)	< 0.00001

Seniors (41 - 59)	255	85 - 465	59 (96.72)	2 (3.28)	< 0.00001
Old (60 ⁺)	242.5	168 - 372	12 (100)	0 (0)	-
Total			177 (94.65)	10 (5.35)	

*M = Male, F = Female. *Calculated from z score.*

However, at the onset of the disease, no significant correlation was observed between the level of leukocytopenia and the intensity of arthralgic pain. Red blood cell (RBC) count was remarkably above the reference range in the mid aged and senior groups. The interquartile range of the RBC was between 3.2 to 6.22 M/ μ L and the median value was 4.5 M/ μ L. Erythrocyte sedimentation rate (ESR) was significantly higher in all age groups, especially in female patients (**Table 5**). Further, a significant correlation was obtained between the different age groups and RBC counts, neutrophil counts and leucocyte counts of the ChikV positive patients (**S3 Table**).

Fig 4: Scatter diagram of hematological findings of ChikV positive patients. Shadowed area denotes the reference ranges. a) Haemoglobin level in females. b) Haemoglobin levels in males. c) RBC counts in females. d) RBC counts in males. e) WBC counts in females. f) WBC counts in males. g) Platelet counts in females. h) Platelet counts in males

Characteristics of long-term arthralgia in ChikV infected patients

Long-term arthralgia associated with ChikV infection. All patients enrolled in the LCA group were interviewed using a questionnaire at M2, M4, M6, M9 and M12 post-ChikV infection to monitor persistence of fever, arthralgia and other clinical symptoms. None of our monitored patients reported a relapse of the fever. The percentage of patients suffering from long-term arthralgia decreased significantly (till M6) after the acute phase of the infection and then raised to ~19% at M9 and M12. Most of our enrollees complained of intermittent arthralgia, with successive recovery and relapse; none of the patients complained of permanent

arthralgia at any timepoint after the acute phase and all of the respondents reported that the intensity of the pain was significantly reduced after M2. Of note, all of our enrolled patients in the LCA group suffered from arthralgia between day 0 to 7 and none of them suffered from joint pains prior to the ChikV infection. The McNemar test for matched pairs of subjects revealed that the site of arthralgic pain (**S4 Table**) remained the same at each time point. The percentage of patients suffering from myalgia decreased a lot after the acute phase of the infection and stabilized by M6. None of the patients reported to have myalgia at M9 and M12 (**Fig 5**). When ChikV-induced arthralgia relapsed, it was symmetrical, involving more than 2 different anatomical locations. Most frequently, the finger joints, wrists and ankles were affected; regardless of age and sex, some patients complained of pain at elbow joint and knee.

Fig 5: Persistence of Chikungunya symptoms over time course in ChikV positive patients

We noted that the number of sites affected by arthralgia gradually diminished in patients still suffering until M2, with only 23% patients suffering from polyarthralgia. However, the number of anatomical locations further decreased significantly in M4 and M6 and then stabilized at M9 and M12 (50% and 64% respectively, p value < 0.0001).

Other long-term clinical signs associated with ChikV infection. At M6, M9 and M12, the LCA group displayed other symptoms including local swelling of joints, cutaneous and dermatological symptoms and post-infection weakness. Additionally, sleep, memory and/or concentration disorders as well as depression and stinginess were remarkably associated. Furthermore, between M6 and M12, 16.67% ($n = 8$) complained that they frequently suffered tachycardia during working, even though none of them had any previous heart complications.

The number of patients who visited a physician increased significantly between M6 (4; 8.33%) and M12 (16; 33%, data not shown) ($p < 0.005$). However, the most significant after-effect of the infection in our study population appeared to be post infection weakness. Around

40% of the patients reported to have continuous weakness at M2. The percentage decreased significantly at M6, increasing however again to ~17% at M9 and M12. Besides, more than 20% of patients complained about sleep disorder at M2 and M4, but the percentage diminished to less than 10% at M6. However, complaints of disturbed sleep slightly increased at M9 and M12 (**Fig 5**).

Over 10% of patients complained of new symptoms at M2 which they had not suffered from during the acute phase of the infection (**Fig 5**). Even at M6, 6.25% patients reported to suffer new symptoms and more than 4% patients to experience new symptoms at M9. However, we did not attempt to find any association between the newly gained symptoms and the effect of the RNA virus infection. Although the new symptoms were generally sleeping problems, swelling of joints, arthritis-like symptoms and memory problems were also reported. Although the respondents did not display any neurological dysfunction, the mild memory problems could not be excluded to result from the ChikV infection. Some of the patients reported that they were frequently prone to depression and partially lost control over their temper.

Post infection impact on daily life at M6 and M12

Arthralgia coupled with weakness in patients at M6 and M12 were highly incapacitating for daily life activities, professional life and leisure activities (**Table 6**). Most of the patients having chronic arthralgia complained of pain when rising from sitting and lying, walking or picking up a load. Twenty-seven percent and ~23% patients respectively in M6 and M12 reported that the arthralgia affected their professional activities. Remarkably, ~31% patients complained that arthralgia had disturbed them in leisure. Moreover, all the patients having memory problems complained that it had significant impact on their day to day life activities.

Table 6: Impact of arthralgia on daily life for patients at M6 and M12

	M6 (%)	M12 (%)
Issues regarding quality of life		
Discomfort while rising from sitting/lying	22.91	16.67
Weakness in long walks (over 1 KM)	10.41	8.33
Discomfort during picking up a heavy object	20.83	18.75
At least one of these discomforts	29.17	25
Impacts on working life		
With activity	27.1	22.91
Physical impact	22.91	10.41
low impact	54.54	55.55
moderate impact	27.27	22.22
high impact	18.18	22.22
Impact on leisure-time		
No impact	66.67	62.5
Physical impact	33.33	29.17
low impact	18.75	35.71
moderate impact	31.25	28.57
high impact	50	35.71

M: month

185 Discussion

186 The Chikungunya outbreak of 2017 in Bangladesh appeared as an epidemic
187 manifestation with 23 of 65 districts of the country infected. This study presents clinical and
188 epidemiological data of this Chikungunya outbreak.

Bangladesh is a riverine monsoon country, and as such an ideal vicinity for the emergence of arboviral diseases including Dengue and Chikungunya. As both have overlapping pathophysiological mechanisms and proceed simultaneously, it is real challenge for physicians to distinguish among them, especially during the early stages of infection [30].

ChikV was found to infect all ages and both sexes; however, ratios varied. A higher percentage of cases was observed in adult females (56.7%) than males (38%) and female children (43.3%). This is different from previously reported ratios for the Asian lineage where male cases were more frequent [30-34], except for the reports from Pakistan where females were more prone to be infected by the ChikV [35]. The higher percentage of adult female cases may be due to higher levels of exposure to infected vectors in the home environment, since Bengali women spend more time at home and the mosquitoes are commonly found indoors [36-39]. In addition, mosquitoes can trace estrogen which works as a lure and since females exhibit higher levels of estrogen, mosquitoes tend to bite them more [40-41]. The difference in number of cases in the age groups may not reflect vulnerability of any specific group but indicate the general population structure in the country [42], i.e. the infection trend was not biased to any age group.

Irrespective of sex, the combination of fever and severe arthralgia (present in 97.9% of cases) can be regarded as the cardinal hallmark of the Chikungunya 2017 outbreak in Bangladesh. This is consistent with the previous outbreak report (83.3 to 98%), though the values were less in case of the children [31, 43-45] (**Table 2, Table 3**). However, in an Indian outbreak of the virus in Kerala in 2007, arthralgia was found to be the initial symptom in only ~17% patients [33].

We found a symmetrical presentation of arthralgia in most of the cases (62.5%), while a higher percentage of patients reported polyarthralgia (56.25%) than oligoarthralgia (43.75%).

213 In addition, we observed that finger joints (93.8%) and wrist (85.4%) joints were the most
214 affected sites. In the acute phase, the frequency of incapacitating pain involving certain
215 peripheral joints (**Fig 3**) was found to be comparable with the study of Queyriaux et al. 2008
216 and Staikowsky et al. 2008; however, it contrasted with earlier reports from India and Suriname
217 [33, 46-49].

218 Other symptoms including headache, itching, catarrh-cough, dizziness, and dysentery
219 were found to be similar to most of previous studies, except for an unusually high frequency
220 of rash (79.2%), swollen joints (72.9%) and redness of eye (64.17%) in the present study [50].

221 Over 85% of the patients complained of severe pain with a median NRS score of 9
222 throughout the acute phase, which was similar as the findings of Staikowsky et al. 2008 [47].
223 Almost two-thirds (64.6%) of our enrolled patients faced sleep disturbances due to arthralgia
224 and myalgia (**Table 3**). The rate of hospitalization (2.1%) was very low and the outbreak did
225 not cause any fatal outcomes. Nonetheless, the overall severity and the extent of arthralgia-
226 related manifestations suggest that an aggressive strain of Chikungunya virus probably
227 circulated during the outbreak.

228 The severity of certain clinical manifestations of Chikungunya might depend on several
229 factors including age, gender, immune status, genetic predisposition etc. [51]. Our analysis
230 showed that children (<15 years) had a lower tendency to have skin rash and itching as well as
231 vomiting. Conversely, a significantly higher frequency of headache was observed among the
232 children compared to other age groups. The duration of pain and rate of any relapse of post-
233 infection symptoms were significantly lower among children as compared to other age groups
234 (**Table 4**).

235 With regards to hematological parameters, distinct markers are yet to be found. Lee et
236 al. (2012) documented several predictable laboratory tests for detecting ChikV, e.g. a drop in

lymphocyte count and a higher count of platelets, leukocytes and neutrophils [52]. In our study, a difference in the hematological findings was documented across all age groups. For instance, hemoglobin level was significantly lower in children and older patients; however, RBC counts were significantly above the reference range in mid-aged and senior groups. We were not able to document any significant drop in the lymphocyte counts nor any significant increase in platelets, leucocytes or neutrophils counts. These outcomes are atypical when compared to the reports from the Ahmedabad outbreak, the Caribbean outbreak in Trinidad in 2015, the La Romana outbreak in 2016 and the Kandy outbreak in Sri Lanka in 2006-07 [31, 44, 53-54]. However, the ESR values obtained through our analysis reports a very broad range with significantly elevated rates in most cases across age and sex ($p < 0.00001$) (**Table 5**).

Based on the follow-up of patients with acute ChikV infection who consented to participate, this study shows the evolution of arthralgia, mapping the frequency and location of arthralgic sites during a 12-month time period. Our data reveals that the proportion of patients having ChikV-induced arthralgia decreased at an almost constant rate at each timepoint (**Fig 5**). Myalgia was not a complaint anymore at M6 and thereafter. This is different compared to the higher percentage of patients with long-term symptoms was reported by several studies of Italian and French cohorts of La Re'union Island or metropolitan France [43, 55-57]. Till M12, ChikV-induced arthralgia was mainly symmetrical, and finger joints, wrist, ankle and knee were found to be most affected; this remains consistent with other studies [43, 54].

There is evidence from different countries - especially France, India, Sri Lanka, Malaysia, Colombia, Venezuela and USA - to suggest that sudden rise of heart rate was associated with the infection at both the acute and the chronic phases [58]. In our cohort, cardiovascular manifestations were not reported by patients during the acute phase and till M6. However, 16.67% of the patients experienced abnormal heart rates between M6 and M12.

Alvarez et al. underlined the urgent need to explore the cardiovascular impact of a ChikV infection in 2017 [58]. To date, these effects remain to be elucidated.

Weakness during professional activities was noted to be the most prominent after effect of the infection, as almost 40% of our patients reported to have severe weakness at M4. The proportion diminished over time but relapsed several times in some patients till M12. In addition, many patients complained from disturbed sleep, swelling of joints and suffered new symptoms, e.g. memory problems. Although the patients in our study did not display any significant neurological symptoms at the acute phase of disease, we were unable to exclude that these memory problems during the chronic phase resulting from ChikV spread in the central nervous system, as it had been reported that ChikV disseminates to the central nervous system in humans and in animals [59-62]. As was obvious in other studies, chronic ChikV induced complications are considered incapacitating for daily life tasks and impact professional activities and quality of life [56-57].

While the previous studies concerning Chikungunya Outbreak 2017 in Bangladesh were limited within the samples recruited from Dhaka only, this study represents a diverse sample population [30, 51]. In addition, our study was extended to the hematological and chronic outcomes of the outbreak rather than to be confined only within the study of clinical and quality of life parameters [30]. However, this study is not free from any limitations. This recruited only the clinically confirmed cases of Chikungunya, but the studied sample pool was relatively smaller than the previous study [30, 51]. Hossain et al., 2018 reported that, the representation of clinically confirmed cases of ChikV was very low during the 2017 outbreak in Bangladesh due to the high cost of testing and scarcity of diagnostic facilities [30], which might be an explanation behind the recruitment of this smaller sample pool. Moreover, data regarding the clinical, chronic impact and daily life related parameters were collected through

285 retrospective technique, which might be prone to recall bias. Further, it is not unlikely that
 286 some respondents have overvalued some clinical symptoms due to the psychological impacts
 287 of massive social media coverage of the outbreak. But this study was conducted during the
 288 very peak of the outbreak and the patients were monitored and interviewed rigorously at regular
 289 intervals, we assume the recall bias was minimized.

290 In summary, this study alludes to the clinical and epidemiological characteristics of the
 291 Chikungunya outbreak of 2017 in Bangladesh. It facilitates our comprehension of the
 292 pathophysiology of the disease across age groups and its chronic consequences till M12, a
 293 prerequisite for the development of efficient management and therapeutic strategies and for
 294 assessing the damage inflicted upon the population by a Chikungunya outbreak.

295 **Conflict of Interest**

296 The authors declare that the research was conducted in the absence of any commercial
297 or financial relationships that could be construed as a potential conflict of interest.

298 **Author Contributions**

299 **Conceived and designed the study:** MH. **Questionnaire preparation:** MH, SA. **Survey:**
300 MK, SA, JT. **Follow-up data collection:** SA, JM. **Data curation:** MK, SA, JT. **Formal**
301 **analysis:** MU, SA, JT. **Contributed reagents/materials/analysis tools:** MH, MU, SA, JT.
302 **Data visualization:** SA. **Script writing:** SA. **Drafted the manuscript:** MH, SA, JT, OV.
303 **Finally approved the manuscript:** All authors.

304 **Acknowledgments**

305 The authors praise the cooperation by Mr. Mohammad Nazmul Huda of the Uttara Crescent
306 Hospital, Uttara, Dhaka as well as the authorities of the other seven participating diagnostic
307 centers for their helping hands during the patient enrollment. The authors are grateful for the
308 invaluable cooperation of the participants for having confidence and trust in the interviewers
309 and sharing sensitive information with the research team. Special thanks to Ms. Tohura Tahsin
310 for her efforts to improve the quality of our manuscript. The authors would like to thank Dr.
311 Md. Shakhinur Islam Mondal (Associate Professor, Department of Genetic Engineering and
312 Biotechnology, Shahjalal University of Science and Technology) for his kind assistance.

313 **References**

- 314 [1] Brighton SW, Prozesky OW, De La Harpe AL. Chikungunya virus infection-A
315 retrospective study of 107 cases. South African Medical Journal. 1983;68(9):313-5.
- 316 [2] Pialoux G, Gaüzère BA, Jauréguiberry S, Strobel M. Chikungunya, an epidemic
317 arbovirosis. The Lancet infectious diseases. 2007 May 1;7(5):319-27. doi: 10.1016/s1473-
318 3099(07)70107-x.
- 319 [3] Thiberville SD, Moyen N, Dupuis-Maguiraga L, Nougairede A, Gould EA, Roques P, de
320 Lamballerie X. Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and
321 therapy. Antiviral research. 2013 Sep 1;99(3):345-70. doi: 10.1016/j.antiviral.2013.06.009.
- 322 [4] Patterson J, Sammon M, Garg M. Dengue, Zika and chikungunya: emerging arboviruses in
323 the New World. Western Journal of Emergency Medicine. 2016 Nov;17(6):671. doi:
324 10.5811/westjem.2016.9.30904.
- 325 [5] Keller, D. M. Debilitating Chikungunya Virus Hits the US. Medscape. 2014. Available:
326 <https://www.medscape.com/viewarticle/833612> [Accessed December 2018].
- 327 [6] Borgherini G, Poubeau P, Staikowsky F, Lory M, Moullec NL, Becquart JP, Wengling C,
328 Michault A, Paganin F. Outbreak of chikungunya on Reunion Island: early clinical and
329 laboratory features in 157 adult patients. Clinical infectious diseases. 2007 Jun
330 1;44(11):1401-7. doi: 10.1086/517537.
- 331 [7] Wahid B, Ali A, Rafique S, Idrees M. Global expansion of chikungunya virus: mapping
332 the 64-year history. International Journal of Infectious Diseases. 2017 May 1;58:69-76. doi:
333 10.1016/j.ijid.2017.03.006.

- 334 [8] Lebrun G, Chadda K, Reboux AH, Martinet O, Gaüzère BA. Guillain-Barré syndrome after
335 chikungunya infection. *Emerging infectious diseases*. 2009 Mar;15(3):495. doi:
336 10.3201/eid1503.071482.
- 337 [9] Dupuis-Maguiraga L, Noret M, Brun S, Le Grand R, Gras G, Roques P. Chikungunya
338 disease: infection-associated markers from the acute to the chronic phase of arbovirus-
339 induced arthralgia. *PLoS neglected tropical diseases*. 2012 Mar 27;6(3):e1446. doi:
340 10.1371/journal.pntd.0001446.
- 341 [10] Renault P, Solet JL, Sissoko D, Balleydier E, Larrieu S, Filleul L, Lassalle C, Thiria J,
342 Rachou E, de Valk H, Ille D. A major epidemic of chikungunya virus infection on Reunion
343 Island, France, 2005–2006. *The American journal of tropical medicine and hygiene*. 2007
344 Oct 1;77(4):727-31. doi: 10.4269/ajtmh.2007.77.727.
- 345 [11] Kosasih H, de Mast Q, Widjaja S, Sudjana P, Antonjaya U, Ma'roef C, Riswari SF,
346 Porter KR, Burgess TH, Alisjahbana B, van der Ven A. Evidence for endemic chikungunya
347 virus infections in Bandung, Indonesia. *PLoS neglected tropical diseases*. 2013 Oct
348 24;7(10):e2483. doi: 10.1371/journal.pntd.0002483.
- 349 [12] Gérardin P, Fianu A, Malvy D, Mussard C, Boussaïd K, Rollot O, Michault A, Gaüzere
350 BA, Bréart G, Favier F. Perceived morbidity and community burden after a Chikungunya
351 outbreak: the TELECHIK survey, a population-based cohort study. *BMC medicine*. 2011
352 Dec;9(1):5. doi: 10.1186/1741-7015-9-5.
- 353 [13] Marimoutou C, Ferraro J, Javelle E, Deparis X, Simon F. Chikungunya infection: self-
354 reported rheumatic morbidity and impaired quality of life persist 6 years later. *Clinical
355 Microbiology and Infection*. 2015 Jul 1;21(7):688-93. doi: 10.1016/j.cmi.2015.02.024.

- 356 [14] Thiberville SD, Boisson V, Gaudart J, Simon F, Flahault A, De Lamballerie X.
357 Chikungunya fever: a clinical and virological investigation of outpatients on Reunion
358 Island, South-West Indian Ocean. PLoS neglected tropical diseases. 2013 Jan
359 17;7(1):e2004. doi: 10.1371/journal.pntd.0002004.
- 360 [15] Ledrans M, Quatresous I, Renault P, Pierre V. Outbreak of chikungunya in the French
361 Territories, 2006: lessons learned. Weekly releases (1997–2007). 2007 Sep 6;12(36):3262.
362 doi: 10.2807/esw.12.36.03262-en.
- 363 [16] Mavalankar D, Shastri P, Bandyopadhyay T, Parmar J, Ramani KV. Increased mortality
364 rate associated with chikungunya epidemic, Ahmedabad, India. Emerging infectious
365 diseases. 2008 Mar;14(3):412. doi: 10.3201/eid1403.070720.
- 366 [17] WHO Media Center. Chikungunya. World Health Organization. 2017. Available:
367 <https://www.who.int/news-room/fact-sheets/detail/chikungunya> [Accessed December 26,
368 2018].
- 369 [18] Brito CA, Teixeira MG. Increased number of deaths during a chikungunya epidemic in
370 Pernambuco, Brazil. Memorias do Instituto Oswaldo Cruz. 2017 Sep;112(9):650-1. doi:
371 10.1590/0074-02760170124.
- 372 [19] icddr, b. First identified outbreak of chikungunya in Bangladesh, 2008. Health Sci Bull.
373 2009 Mar;7(1):1-6.
- 374 [20] Khatun S, Chakraborty A, Rahman M, Banu NN, Rahman MM, Hasan SM, Luby SP,
375 Gurley ES. An outbreak of chikungunya in rural Bangladesh, 2011. PLoS neglected tropical
376 diseases. 2015 Jul 10;9(7):e0003907. doi: 10.1371/journal.pntd.0003907.

- 377 [21] Kabir I, Dhimal M, Müller R, Banik S, Haque U. The 2017 Dhaka chikungunya
378 outbreak. *Lancet Infect Dis.* 2017 Nov 1;17(1118):30564-9. doi: 10.1016/s1473-
379 3099(17)30564-9.
- 380 [22] Uddin KS. Chikungunya-yet another mosquito borne epidemic burden for Bangladesh.
381 *KYAMC Journal.* 2017 Aug 31;8(1):1-3. doi: 10.3329/kyamcj.v8i1.33864.
- 382 [23] Rahman, Z. Chikungunya hits nearly every family in Dhaka. *The Third Pole.* 2017.
- 383 [24] Kalam, M. A. New Threat: Chikungunya Outbreak. *The Independent.* 2017. Available:
384 www.theindependentbd.com/printversion/details/104392 [Accessed December 2018].
- 385 [25] Chowdhury, K. R. Chikungunya Outbreak Spreads Beyond Bangladeshi Capital:
386 Health Officials. *BenarNews24.* 2007. Available:
387 benarnews.org/english/news/bengali/bangladesh-health07212017170830.html [Accessed
388 December 2018].
- 389 [26] European Centre for Disease Prevention and Control. Cluster of autochthonous
390 chikungunya cases in France. 2017.
- 391 [27] Shishir, M. Chikungunya breaks out in epidemic form. *Prothom Alo.* 2017. Available:
392 en.prothomalo.com/bangladesh/news/153339/Chikungunya-breaks-out-in-epidemic-form
393 [Accessed December 2018].
- 394 [28] Huang JH, Yang CF, Su CL, Chang SF, Cheng CH, Yu SK, Lin CC, Shu PY. Imported
395 chikungunya virus strains, Taiwan, 2006–2009. *Emerging infectious diseases.* 2009
396 Nov;15(11):1854. doi: 10.3201/eid1511.090398.
- 397 [29] Melan A, Aung MS, Khanam F, Paul SK, Riaz BK, Tahmina S, Kabir MI, Hossain
398 MA, Kobayashi N. Molecular characterization of chikungunya virus causing the 2017

- 399 outbreak in Dhaka, Bangladesh. *New microbes and new infections*. 2018 Jul 1;24:14-6.
- 400 doi: 10.1016/j.nmni.2018.03.007.
- 401 [30] Hossain MS, Hasan MM, Islam MS, Islam S, Mozaffor M, Khan MA, Ahmed N,
- 402 Akhtar W, Chowdhury S, Arafat SY, Khaleque MA. Chikungunya outbreak (2017) in
- 403 Bangladesh: Clinical profile, economic impact and quality of life during the acute phase of
- 404 the disease. *PLoS neglected tropical diseases*. 2018 Jun 6;12(6):e0006561. doi:
- 405 10.1371/journal.pntd.0006561.
- 406 [31] Langsjoen RM, Rubinstein RJ, Kautz TF, Auguste AJ, Erasmus JH, Kiaty-Figueroa L,
- 407 Gerhardt R, Lin D, Hari KL, Jain R, Ruiz N. Molecular virologic and clinical characteristics
- 408 of a chikungunya fever outbreak in La Romana, Dominican Republic, 2014. *PLoS*
- 409 *neglected tropical diseases*. 2016 Dec 28;10(12):e0005189. doi:
- 410 10.1371/journal.pntd.0005189.
- 411 [32] Kumar PS, Arjun MC, Gupta SK, Nongkynrih B. Malaria, dengue and chikungunya in
- 412 India—An update. *Indian Journal of Medical Specialties*. 2018 Jan 1;9(1):25-9. doi:
- 413 10.1016/j.injms.2017.12.001.
- 414 [33] Vijayakumar KP, Anish TS, George B, Lawrence T, Muthukkutty SC, Ramachandran
- 415 R. Clinical profile of chikungunya patients during the epidemic of 2007 in Kerala, India.
- 416 *Journal of global infectious diseases*. 2011 Jul;3(3):221. doi: 10.4103/0974-777x.83526.
- 417 [34] Jain J, Nayak K, Tanwar N, Gaiind R, Gupta B, Shastri JS, Bhatnagar RK, Kaja MK,
- 418 Chandele A, Sunil S. Clinical, serological, and virological analysis of 572 chikungunya
- 419 patients from 2010 to 2013 in India. *Clinical Infectious Diseases*. 2017 Jul 1;65(1):133-40.
- 420 doi: 10.1093/cid/cix283.

- 421 [35] Badar N, Salman M, Ansari J, Ikram A, Qazi J, Alam MM. Epidemiological trend of
422 chikungunya outbreak in Pakistan: 2016–2018. PLoS neglected tropical diseases. 2019 Apr
423 18;13(4):e0007118.
- 424 [36] Brunkard JM, López JL, Ramirez J, Cifuentes E, Rothenberg SJ, Hunsperger EA,
425 Moore CG, Brussolo RM, Villarreal NA, Haddad BM. Dengue fever seroprevalence and
426 risk factors, Texas–Mexico border, 2004. Emerging infectious diseases. 2007
427 Oct;13(10):1477. doi: 10.3201/eid1310.061586.
- 428 [37] Raude J, Setbon M. The role of environmental and individual factors in the social
429 epidemiology of chikungunya disease on Mayotte Island. Health & place. 2009 Sep
430 1;15(3):689-99. doi: 10.1016/j.healthplace.2008.10.009.
- 431 [38] Fritel X, Rollot O, Gérardin P, Gaüzère BA, Bideault J, Lagarde L, Dhuime B, Orvain
432 E, Cuillier F, Ramful D, Sampériz S. Chikungunya virus infection during pregnancy,
433 Reunion, France, 2006. Emerging infectious diseases. 2010 Mar;16(3):418. doi:
434 10.3201/eid1603.091403.
- 435 [39] Salje H, Lessler J, Paul KK, Azman AS, Rahman MW, Rahman M, Cummings D,
436 Gurley ES, Cauchemez S. How social structures, space, and behaviors shape the spread of
437 infectious diseases using chikungunya as a case study. Proceedings of the National
438 Academy of Sciences. 2016 Nov 22;113(47):13420-5. doi: 10.1073/pnas.1611391113.
- 439 [40] Lindsay S, Ansell J, Selman C, Cox V, Hamilton K, Walraven G. Effect of pregnancy
440 on exposure to malaria mosquitoes. The Lancet. 2000 Jun 3;355(9219):1972. doi:
441 10.1016/s0140-6736(00)02334-5.
- 442 [41] Fradin MS. Mosquitoes and mosquito repellents: a clinician's guide. Annals of internal
443 medicine. 1998 Jun 1;128(11):931-40. doi: 10.7326/0003-4819-128-11-199806010-00013.

- 444 [42] Bangladesh Bureau of Statistics (BBS). Population distribution and internal migration
445 in Bangladesh. 2007.
- 446 [43] Larrieu S, Poudereux N, Pistone T, Filleul L, Receveur MC, Sissoko D, Ezzedine K,
447 Malvy D. Factors associated with persistence of arthralgia among Chikungunya virus-
448 infected travellers: report of 42 French cases. *Journal of Clinical Virology*. 2010 Jan
449 1;47(1):85-8. doi: 10.1016/j.jcv.2009.11.014.
- 450 [44] Sahadeo N, Mohammed H, Allicock OM, Auguste AJ, Widen SG, Badal K, Pulchan
451 K, Foster JE, Weaver SC, Carrington CV. Molecular characterisation of chikungunya virus
452 infections in Trinidad and comparison of clinical and laboratory features with dengue and
453 other acute febrile cases. *PLoS neglected tropical diseases*. 2015 Nov 18;9(11):e0004199.
454 doi: 10.1371/journal.pntd.0004305.
- 455 [45] Mattar S, Miranda J, Pinzon H, Tique V, Bolaños A, Aponte J, Arrieta G, Gonzalez M,
456 Barrios K, Contreras H, Alvarez J. Outbreak of Chikungunya virus in the north Caribbean
457 area of Colombia: clinical presentation and phylogenetic analysis. *The Journal of Infection*
458 in Developing Countries. 2015 Oct 29;9(10):1126-32. doi: 10.3855/jidc.6670.
- 459 [46] Queyriaux B, Simon F, Grandadam M, Michel R, Tolou H, Boutin JP. Clinical burden
460 of chikungunya virus infection. *The Lancet infectious diseases*. 2008 Jan 1;8(1):2-3.
- 461 [47] Staikowsky F, Le Roux K, Schuffenecker I, Laurent P, Grivard P, Develay A, Michault
462 A. Retrospective survey of Chikungunya disease in Reunion Island hospital staff.
463 *Epidemiology & Infection*. 2008 Feb;136(2):196-206. doi: 10.1017/s0950268807008424.
- 464 [48] Chopra A, Anuradha V, Ghorpade R, Saluja M. Acute Chikungunya and persistent
465 musculoskeletal pain following the 2006 Indian epidemic: a 2-year prospective rural
466 community study. *Epidemiology & Infection*. 2012 May;140(5):842-50.

- 467 [49] van Genderen FT, Krishnadath I, Sno R, Grunberg MG, Zijlmans W, Adhin MR. First
468 chikungunya outbreak in Suriname; clinical and epidemiological features. PLoS neglected
469 tropical diseases. 2016 Apr 15;10(4):e0004625.
- 470 [50] Teng TS, Kam YW, Lee B, Hapuarachchi HC, Wimal A, Ng LC, Ng LF. A systematic
471 meta-analysis of immune signatures in patients with acute chikungunya virus infection. The
472 Journal of infectious diseases. 2015 Jan 29;211(12):1925-35. doi: 10.1093/infdis/jiv049.
- 473 [51] Deeba IM, Hasan MM, Al Mosabbir A, Banna Siam MH, Islam MS, Raheem E,
474 Hossain MS. Manifestations of Atypical Symptoms of Chikungunya during the Dhaka
475 Outbreak (2017) in Bangladesh. The American journal of tropical medicine and hygiene.
476 2019 Apr 29:tpmd190122.
- 477 [52] Lee VJ, Chow A, Zheng X, Carrasco LR, Cook AR, Lye DC, Ng LC, Leo YS. Simple
478 clinical and laboratory predictors of Chikungunya versus dengue infections in adults. PLoS
479 neglected tropical diseases. 2012 Sep 27;6(9):e1786. doi: 10.1016/j.ijid.2012.05.885.
- 480 [53] Kularatne SA, Gihan MC, Weerasinghe SC, Gunasena S. Concurrent outbreaks of
481 Chikungunya and Dengue fever in Kandy, Sri Lanka, 2006–07: a comparative analysis of
482 clinical and laboratory features. Postgraduate medical journal. 2009 Jul 1;85(1005):342-6.
483 doi: 10.1136/pgmj.2007.066746.
- 484 [54] Shah PS, Shah ND, Patel AS, Kurtadikar SM, Patel KR, Murarka SM, Shah BS, Rao
485 MV. Outbreak of Chikungunya in Ahmedabad: A Report. Biotechnological Research. 2017
486 Feb 13;3(2):35-8. Available: [biotechnologicalresearch.com/index.php/BR/article/
487 download/56/54](http://biotechnologicalresearch.com/index.php/BR/article/download/56/54)
- 488 [55] Borgherini G, Poubeau P, Jossaume A, Gouix A, Cotte L, Michault A, Arvin-Berod C,
489 Paganin F. Persistent arthralgia associated with chikungunya virus: a study of 88 adult

- 490 patients on reunion island. *Clinical Infectious Diseases*. 2008 Aug 15;47(4):469-75. doi:
491 10.1086/590003.
- 492 [56] Moro ML, Grilli E, Corvetta A, Silvi G, Angelini R, Mascella F, Miserocchi F, Sambo
493 P, Finarelli AC, Sambri V, Gagliotti C. Long-term chikungunya infection clinical
494 manifestations after an outbreak in Italy: a prognostic cohort study. *Journal of Infection*.
495 2012 Aug 1;65(2):165-72. doi: 10.1016/j.jinf.2012.04.005.
- 496 [57] Couturier E, Guillemin F, Mura M, Léon L, Virion JM, Letort MJ, De Valk H, Simon
497 F, Vaillant V. Impaired quality of life after chikungunya virus infection: a 2-year follow-
498 up study. *Rheumatology*. 2012 Mar 16;51(7):1315-22. doi: 10.1093/rheumatology/kes015.
- 499 [58] Alvarez MF, Bolívar-Mejía A, Rodriguez-Morales AJ, Ramirez-Vallejo E.
500 Cardiovascular involvement and manifestations of systemic Chikungunya virus infection:
501 a systematic review. *F1000Research*. 2017;6. doi: 10.12688/f1000research.11078.2.
- 502 [59] Barr KL, Khan E, Farooqi JQ, Imtiaz K, Prakoso D, Malik F, Lednicky JA, Long MT.
503 Evidence of chikungunya virus disease in Pakistan since 2015 with patients demonstrating
504 involvement of the central nervous system. *Frontiers in public health*. 2018; 6:186. doi:
505 10.3389/fpubh.2018.00186.
- 506 [60] Couderc T, Chrétien F, Schilte C, Disson O, Brigitte M, Guivel-Benhassine F, Touret
507 Y, Barau G, Cayet N, Schuffenecker I, Desprès P. A mouse model for Chikungunya: young
508 age and inefficient type-I interferon signaling are risk factors for severe disease. *PLoS*
509 *pathogens*. 2008 Feb 15;4(2):e29. doi: 10.1371/journal.ppat.0040029.
- 510 [61] Labadie K, Larcher T, Joubert C, Mannioui A, Delache B, Brochard P, Guigand L,
511 Dubreil L, Lebon P, Verrier B, de Lamballerie X. Chikungunya disease in nonhuman

512 primates involves long-term viral persistence in macrophages. The Journal of clinical
513 investigation. 2010 Mar 1;120(3):894-906. doi: 10.1172/jci40104.

514 [62] Economopoulou A, Dominguez M, Helynck B, Sissoko D, Wichmann O, Quenel P,
515 Germonneau P, Quatresous I. Atypical Chikungunya virus infections: clinical
516 manifestations, mortality and risk factors for severe disease during the 2005–2006 outbreak
517 on Reunion. Epidemiology & Infection. 2009 Apr;137(4):534-41. doi: 10.1017/
518 s0950268808001167.

519 **Supplementary Material**

520 1. S1 Checklist: STROBE Checklist (.docx file)

521 2. S2 Questionnaire: Questionnaire form used for the LCA (.docx file)

522 3. S3 Table: (Correlation between age and hematological data

523 4. S4 Table: A) Sites of pain at different time points. B) Outcomes of McNemar test.

524 **Data Availability Statement**

525 All supplementary data are given in the Supplementary Material Section. Any
526 additional datasets from this study can be obtained upon request to the corresponding author.

Chikungunya Outbreak 2017 in Bangladesh

Report of outbreak in **17** districts

Dhaka and Mymensingh: **2**
neighboring large cities with most
occurrences

Primary enrollment of **297**
patients from **8** diagnostic centers
in Dhaka and Mymensingh

Final enrollment based on
inclusion criteria:
187 patients

LCA: **48** ChikV patients

Questionnaire-based interview for
clinical information

Face-to-face/over phone interview
to monitor until **12** months

General interview and sample
collection

Hematological testing

Data analysis

bioRxiv preprint first posted online May. 15, 2019; doi: <https://doi.org/10.1101/639872>. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Fig 1




Fig 2




Fig 3




Fig 4

% of patients




Fig 5